UY39096A - Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato - Google Patents

Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato

Info

Publication number
UY39096A
UY39096A UY0001039096A UY39096A UY39096A UY 39096 A UY39096 A UY 39096A UY 0001039096 A UY0001039096 A UY 0001039096A UY 39096 A UY39096 A UY 39096A UY 39096 A UY39096 A UY 39096A
Authority
UY
Uruguay
Prior art keywords
quinazolin
piperazin
fluoro
crystalline form
metoxifenil
Prior art date
Application number
UY0001039096A
Other languages
English (en)
Inventor
Helmut Buschmann
Thomas Goldner
Carles Ceron Bertran Jordi
Original Assignee
Aic246 Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Gmbh & Co Kg filed Critical Aic246 Gmbh & Co Kg
Publication of UY39096A publication Critical patent/UY39096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un método eficaz para preparar una forma cristalina de trihidrato de sodio del ácido 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il]acético.
UY0001039096A 2020-02-27 2021-02-26 Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato UY39096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20159727 2020-02-27

Publications (1)

Publication Number Publication Date
UY39096A true UY39096A (es) 2021-09-30

Family

ID=69742722

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039096A UY39096A (es) 2020-02-27 2021-02-26 Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato

Country Status (19)

Country Link
US (1) US20230219899A1 (es)
EP (1) EP4110470A1 (es)
JP (1) JP2023519813A (es)
KR (1) KR20220148863A (es)
CN (1) CN115581118A (es)
AR (1) AR121439A1 (es)
AU (1) AU2021225363A1 (es)
BR (1) BR112022016929A2 (es)
CA (1) CA3169484A1 (es)
CL (1) CL2022002291A1 (es)
CO (1) CO2022012039A2 (es)
CU (1) CU20220049A7 (es)
EC (1) ECSP22066680A (es)
IL (1) IL295795A (es)
MX (1) MX2022010441A (es)
PE (1) PE20230515A1 (es)
TW (1) TW202140453A (es)
UY (1) UY39096A (es)
WO (1) WO2021170874A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Also Published As

Publication number Publication date
CO2022012039A2 (es) 2022-11-18
WO2021170874A1 (en) 2021-09-02
KR20220148863A (ko) 2022-11-07
MX2022010441A (es) 2022-10-18
EP4110470A1 (en) 2023-01-04
AR121439A1 (es) 2022-06-08
CA3169484A1 (en) 2021-09-02
JP2023519813A (ja) 2023-05-15
BR112022016929A2 (pt) 2022-12-06
US20230219899A1 (en) 2023-07-13
TW202140453A (zh) 2021-11-01
ECSP22066680A (es) 2022-12-30
CN115581118A (zh) 2023-01-06
IL295795A (en) 2022-10-01
PE20230515A1 (es) 2023-03-24
CU20220049A7 (es) 2023-04-10
CL2022002291A1 (es) 2023-02-03
AU2021225363A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
RU2397976C2 (ru) Производные бензамидов и гетероаренов
AR084639A1 (es) Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo
CY1117796T1 (el) Μετα νατριου και ασβεστιου αλατα παραγωγου διυδροκινζολινης και η χρηση αυτων ως αντι-ιικα μεσα
CU24316B1 (es) Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen
BR112015000160A2 (pt) fabricação de ácido 2-(5-bromo-4-(4-ciclopropil hidronaftalen-1-il)-4h-1,2,4-triazol-3-il-tio) acético
AR084174A1 (es) Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
EA201891642A1 (ru) Кристаллические формы ингибитора mdm2
CL2012002840A1 (es) Procedimiento de preparacion del compuesto de fórmula (i) 4-(4-((((4-cloro-3-(trifluorometil)fenil)amino)carbonil)amino)-3-fluorofenoxi)-n-metilpiridina-2-carboxamida y sus sales a partir de 4-(4-amino-3-fluorofenoxi)-n-metilpiridina-2-carboxamida y 1-cloro-4-isocianato-2-(trifluorometil)benceno; y el compuesto de fórmula (i).
DOP2014000286A (es) Compuestos de acido dimetil-benzoico
AR088018A1 (es) Proceso e intermediarios para preparar lapatinib
PE20091213A1 (es) Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico
CL2014002306A1 (es) Una composicion farmaceutica intravenosa que comprende al compuesto acido {8-fluoro-2-[4-(3-metoxifenil)-piperazina-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolina-4-il}acetico, al menos un excipiente seleccionado de ciclodextrinas, lisina y arginina, y agua; su metodo de preparacion; y su uso para el tratamiento y/o profilaxis de infecciones por virus.
ES2603227T3 (es) Proceso para la preparación de compuestos cetólidos
MX2020013311A (es) Composicion farmaceutica para administracion topica.
UY39096A (es) Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
CO2021011836A2 (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
PE20141385A1 (es) Bloqueantes de los canales de sodio dependientes de voltaje
RU2009147291A (ru) Применение ингибиторов raf для лечения рака щитовидной железы
EA201100230A1 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
EA201301136A3 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same
MX2019003457A (es) Enantiómero de ácido fenilpropiónico sustituido y método de fabricación, composición, y aplicación del mismo.
WO2016051422A3 (en) Process for the preparation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide and its polymorphs thereof
EA201400473A1 (ru) Способ синтеза 3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-карбонитрила и применение для синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
CU20220046A7 (es) Sal de potasio del acido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1- il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético y métodos para su preparación